Evaxion Biotech A/S Q3 2023 Earnings Call Transcript

Quartr
Provided by Quartr
September 6, 2023

There are 6 speakers on the call.

Operator

Good day, and thank you for standing by. Welcome to the Photronics Third Quarter Fiscal Year 2023 Earnings Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer Please be advised that today's conference is being recorded on Wednesday, September 6, 2023. I would now like to turn the conference over to Rochelle Burke, Chief Administrative Officer.

Operator

Please go ahead.

Speaker 1

Thank you, Michelle. Good morning, everyone. Welcome to our review of Photronics' fiscal 2023 3rd quarter results. Joining me this morning are Frank Lee, our Chief Executive Officer John Jordan, our Chief Financial Officer Chris Prozler, our Chief Technology Officer and Eric Rivera, our Chief Accounting Officer and Corporate Controller. The press release we issued earlier this morning, together with the presentation material that accompanies our remarks, are available on the Investor Relations section of our webpage.

Speaker 1

Comments made by any participants on today's call may include forward looking statements that include such words as anticipate, believe, Estimates, expect, forecast and in our view. These forward looking statements are based upon a number of risks, expressed or implied, and we assume no obligation to update any forward looking information. During the course of our discussion, We will refer to certain non GAAP financial metrics. These numbers are useful for analysts, investors and management to evaluate ongoing performance. A reconciliation of these metrics to GAAP financial results is provided in our presentation materials.

Speaker 1

At this time, I will turn the call over to Frank.

Speaker 2

Thank you, Rachel, and good morning, everyone. Our team did a great job in the 3rd quarter, Maintaining margin and improving cash flow, even while we experienced slightly softer demand. Revenue during the quarter was $224,000,000 2% better than RCS 3rd quarter, sequentially 2% lower than the record of $229,000,000 set in our previous quarter. Looking at our full year to date, revenues are up 8% compared to last year. At the midpoint of the revenue range in our Q4 guidance, we are on track to achieve our 6th Consecutive year of record revenue.

Speaker 2

We continue to deliver consistent financial performance against the backdrop of an extended semiconductor downturn. Profitability has improved year to date with gross margins up 3% from last year and operation margins up nearly 4%. Turning to the IC business. High end IC revenue was up from Q2 As demand increased from foundry customer in Asia, at the same time, reduced management demand in Asia caused our overall IC revenue to fall slightly. We believe we have maintained market share.

Speaker 2

Our geographic presence and the broad technologies have positioned the company well to continue to grow as market demand improves. FPD saw continued growth in high end AMOLED masks for mobile display. This was offset by declines in photomask for G10.5 plus and LTPS Displays. MRN usage is expanding into larger format high end tablet, laptop and automotive sectors, While increasing penetration into smartphones, we also see emerging panel makers In future years, another positive trend will be the production of AMOLED Panels are on G8.6 size glass. This product will require a new level of High quality and superior photomask favoring for Chinese technology leadership position.

Speaker 2

We are confident in our ability to continue to win business with these advanced technologies. The strong AMOLED demand and continued mainstream business kept our F and D fab operation At high utilization levels in Q3 and we expect to maintain the trend into Q4. We overcame overall modestly lower revenue by further controlling cost and optimizing our product mix. That enabled us to maintain growth and operation margins in line with the record levels set in Q2. In addition, Our customer long term agreement help us preserve the ASP and fab utilization rates.

Speaker 2

As a result, we earned $0.44 per share on a GAAP basis and $0.51 per share On a non GAAP basis, recovery in our global semiconductor industry seems to be slower than previous anticipated due to continued macroeconomic uncertainty and mute consumer demand. However, on a positive side, IC design intensive industries trend should be a positive driver for performance growth. Technologies such as AI, data center, IoT, automotive, industrial and machine learning We are continuing to drive chipmakers to release design for many varieties of new ICs. Since each design requires a unique set of photomask to launch this IC product, this will drive demand for both high end And mainstream business. Additionally, onshorely trends Our supporting is spending investment in global semiconductor manufacturing capacity across multiple nodes.

Speaker 2

Large wafer fab projects are under construction of plant in Asia, North America and Europe to help each region manage their semiconductor supply chain. Consequently, We also expect this additional capacity to drive more global demand for photomask. Our financial discipline, capital allocation strategy and careful cash Balance sheet management support our long term growth initiative to take advantage of these trends. The priority of Photronics' capital allocation strategy has been to invest in profitable organic growth. We believe our ability to outgrow the IC market and win Photomar share All of the above factors give us confidence that Photomass demand will continue to grow over the long term.

Speaker 2

And Photronics is uniquely positioned to benefit from this growth opportunity. 2023 is on track to be another great year for Photronics, and the company is performing well Even under a difficult industry environment, I have full confidence in our team's ability, And I am optimistic that we will be able to grow revenues, expand margin and deploy capital to With that, I will turn the call over to John.

Speaker 3

Thank you, Frank. Good morning, everyone. Our guidance for Q3 anticipated revenue essentially flat With Q2, revenue for the quarter of $224,000,000 was at the low end of that guidance, an increase of 2% over last year's Q3 and 2% off the Q2 quarterly record of $229,000,000 Both IC and FPD were off the Q2 result by that same percentage. A lag in anticipated orders was We anticipate the Q4 order rate to be somewhat better as reflected in our Q4 guidance Consistent with the countercyclical nature of the photomask industry we've discussed in the past, Photronics revenue has remained relatively strong in the face of a sustained industry downturn. IC revenue of $163,100,000 was down 2% sequentially.

Speaker 3

High end revenue increased sequentially despite weakness in memory on strong foundry logic demand in Asia. Mainstream IC demand was more tempered, but the overall supply demand dynamic and the long term purchase agreement structure Continue to support favorable pricing and together with our understanding of the industry outlook, supplemented by close collaboration with our customers' strategies, help inform where our investments are targeted. The expansion of our Taiwan and China IC facilities will provide the added capacity to continue fueling growth in our IC business in that region. FPD revenue was also down 2% from the record setting 2nd quarter level, Although AMOLED business to supply mobile demand continues strong, high end overall declined as the AMOLED growth was offset by fewer LTPS and G10.5 plus masts. We continue to see strong AMOLED demand As we have each quarter in the past, we toggled the production capacity to mainstream to offset the slight high end softness.

Speaker 3

We anticipate continued growing demand in FPD as panel makers release new designs for mobile and other applications. As Frank mentioned, with our relentless focus on cost management, we maintained gross and operating margins in line with the records achieved in the 2nd quarter Despite 2% lower revenue, over the trailing 12 month period ending with Q3, we have achieved gross margin of 38% And operating margin of 28%. Since our margins are both already into the margin ranges In our fiscal 2024 target model, we will update that model and reissue it at a future time. Nonetheless, we will continue to drive to expand margins as revenue grows based on operating leverage, pricing power and disciplined cost management. Net income in the quarter was $27,000,000 on a GAAP basis or $0.44 Per diluted share, on a non GAAP basis, adjusting for the unrealized non operating loss Due to foreign currency movements, we achieved net income of $31,600,000 or $0.51 per share at the midpoint of our Q3 guidance, a solid result based upon our revenues in the quarter.

Speaker 3

Operating cash flow was strong again this quarter at $85,900,000 based on strong net income and a good job managing working capital. We invested $21,100,000 in CapEx in the quarter, bringing year to date CapEx to $78,800,000

Speaker 2

and year

Speaker 3

to date free cash flow to nearly 117,000,000 Our 2023 CapEx forecast remains approximately $130,000,000 primarily for the increased IC capacity I discussed. On the balance sheet, cash was $448,500,000 at the end of the quarter and Short term investments were $27,300,000 We have $26,700,000 of debt, which consists of low cost equipment leases. The strong financial position provides ample liquidity for our growth investments and resilience against uncertainties we could face in the future. Before I provide guidance, I'll remind you that our visibility is Always limited as our backlog is typically only 1 to 3 weeks and demand for some of our products is inherently uneven and difficult to predict. Additionally, the ASPs for high end mask sets are high And as this segment of the business grows, a relatively low number of high end orders can have a significant impact on our quarterly revenue and earnings.

Speaker 3

Given those caveats, we expect 4th quarter revenue to be in the range of $222,000,000 to $232,000,000 We believe photovest demand will continue to do well in this current semiconductor and display environment and we will continue to strive to increase our market leading position. Based on those revenue expectations and our current operating model, we estimate non GAAP earnings per share for the Q4 to be in the range of $0.51 to $0.59 per diluted share. We are performing well in 2023. Favorable long term demand trends for photomasks, a broad suite of technologies to deliver products our customers need An unmatched global presence to align with our customers' footprints and a great team that consistently exceeds expectations give us confidence that we can achieve our long term targets and continue creating shareholder value. I will now turn the call over to the operator for your questions.

Speaker 4

The first question

Operator

comes from Tom Diffely with D. A. Davidson. Your line is open.

Speaker 4

Hi. This is Linda on behalf of Tom Diffely. Thank you for letting us ask questions. So I guess my first question, it seems like you had pretty good gross margins for the quarter despite the demand slowdown. Could you give us a bit more color on the driving factors there?

Speaker 4

I know you mentioned some cost management and then the pricing is still favorable. Any detail on that would be helpful. Thank you.

Speaker 2

Okay. Thank you. Our price Protect our long term cost agreement with major customers And also the product mix, especially in IC areas, We have more high end product mix compared to previous quarter. So the Compound ASP actually is better. So this is on the ASP revenue side.

Speaker 2

In terms of cost, our procurement team and operation team has worked together to reduce the usage of materials and to improve the operation efficiency To control the cost. So John, you have anything to add?

Speaker 3

No, I think it's really important, Linda, to remember Those long term purchase agreements we have provide a really good support not only for pricing, But for the throughput, the volume that we're getting through our operations that May not be the same with our competitors. So that plus the mix that Frank discussed Helps support really good margins. And you might note that the margin in this previous quarter Was even better than the margin in 2nd quarter by above 10 basis points.

Speaker 4

That's very helpful. And I guess my follow-up, particularly in mainstream, you mentioned software demand in the business. Is it in certain segments or is it across the board? Maybe could you paint a picture on what the future demand in mainstream Looks like and what the margins look like for that business?

Speaker 3

Yes. On a long term basis, Linda, the demand for mainstream is So the Q3, end of Q3 seemed to be a little nadir. We hope it wasn't native, but it seems to be kind of a low point that We expect to mainstream demand to strengthen again during Q4. And then As the industry comes out of its we hope comes out of its slump in 2024, we think we'll see Strong demand across the board.

Speaker 2

Additional comment to John, our backlog Even it's slightly lower than previous quarter, however, it's still maintained at Relatively high level. So under the situation, our cycle time Actually, it's longer than our competitors because the overall market is becoming, Especially, it mentioned it's softer than previous quarter. So before our whip drop down, We are not taking as many orders as we can in the mainstream to be competitive in Cyclotab. However, if the market turn around again in Q4 or early next year, I believe our mainstream Revenue in total will be back to high level again.

Speaker 4

Thank you for the color. And then in terms of the continued geopolitical issues with China and the demand environment being weak On the overall semiconductor market, how would you characterize the health of the Chinese market for you guys, both for semi and FPD At the moment, it may be what you anticipate through the end of this year?

Speaker 2

Chris, you want to

Speaker 3

Linda, our Chinese business is as strong as it's been, And it has continued. We don't see any change in the Chinese business so far. And as we've discussed in the past, the effect on our business of any of the restrictions imposed by the government Thus far, it has been

Speaker 5

bidable. And I guess the other thing we noticed is that fab capacity in China gets For the leading edge, a lot of that capacity is getting pivoted to mid range nodes, and those are very healthy nodes for commercial mask making. So In some ways, there's a lift in certain design activities in mid range nodes, which actually supports our core business. As far as overall semiconductor, it's expected to be down pretty sharply in 2023 and then gradually bounce back in 2024. The photomask industry, the few companies that follow it, is expected to be flat, slightly down in 23.

Speaker 5

So Photronics as a whole is outperforming both of those kind of broad market indicators. So We are kind of tracking what's going on in semiconductor and mask, but generally, we're certainly not sitting still. We're outperforming the broader indices in both of those markets.

Speaker 4

Thank you. And then my last question is about capital expenses. I believe, John, you mentioned, I believe $130,000,000 this year. Is it just for the expansion of the IC facilities in Taiwan and China? Or is there any other capacity you're looking to expand?

Speaker 4

Maybe you talk about this year for FPD and IC?

Speaker 3

No, we have Capital across the board, Linda, a lot of it is in Taiwan and China, but We're putting tools and supplementing lithography lines in all our locations.

Operator

Ladies and gentlemen, there are no further questions at this time. I will now turn the call over to Frank Lee for closing remarks.

Speaker 2

Thank you. Thank you for joining us this morning. I'm proud of our team's performance In delivering strong results in 2023 and look forward to updating you as we make progress

Operator

Ladies and gentlemen, that concludes the conference call for today. We thank you for your participation and ask that You please disconnect your line. Thank you.

Powered by Quartr
Earnings Conference Call
Evaxion Biotech A/S Q3 2023
00:00 / 00:00